PSTV - PLUS THERAPEUTICS, INC.

6.39
0.440   6.886%

Share volume: 263,080
Last Updated: 04-17-2026
Medical Equipment/Surgical, Medical, And Dental Instruments And Supplies: -0.02%

PREVIOUS CLOSE
CHG
CHG%
$5.95
0.44
0.07%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
39%
Profitability 25%
Dept financing 50%
Liquidity 21%
Performance 55%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
17.68%
1 Month
2,550.35%
3 Months
2,140.53%
6 Months
1,003.06%
1 Year
896.88%
2 Year
292.02%
Key data
Stock price
$6.39
P/E Ratio 
N/A
DAY RANGE
$5.76 - $6.44
EPS 
-$0.29
52 WEEK RANGE
$0.13 - $6.44
52 WEEK CHANGE
$896.88
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
171.551 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-14-2025
BETA 
1.31
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$638,360
AVERAGE 30 VOLUME 
$3,924,637
Company detail
CEO: Marc H. Hedrick
Region: US
Website: plustherapeutics.com
Employees: 20
IPO year: 2000
Issue type: Common Stock
Market: XNAS
Industry: Medical Equipment/Surgical, Medical, And Dental Instruments And Supplies
Sector: Manufacturing

Plus Therapeutics, Inc. focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma.

Recent news